

Canine Compulsive Disorder

Karen Lynn C. Sueda, DVM, DACVB
 VCA West Los Angeles Animal Hospital
 Los Angeles, California



▲ **FIGURE 1** A 10-year-old neutered male golden retriever that repetitively licked his right pelvic limb for several months. The dog was painful on lumbosacral palpation and exhibited significant nail wear and quick exposure due to scuffing of both pelvic limbs. The repetitive licking was attributed to pain and stopped after the dog was treated with NSAIDs and paw coverings were applied during walks. Medical differentials, including sources of pain or discomfort, should be ruled out before making a diagnosis of CD, especially in senior dogs or those with recent onset of repetitive behavior.

Canine compulsive disorder (CD) involves abnormal, repetitive behavior resulting from anxiety or stress without an apparent inciting trigger and when other physical or behavioral causes have been excluded.^{1,2}

Background & Pathophysiology

CD behavior may be self-reinforcing and difficult to interrupt without physical intervention, which may cause physical injury. Intensity and/or frequency of the behavior typically disrupts daily functions. Approximately 2% to 5% of patients seen by veterinary behaviorists are diagnosed with CD³; however, CD may be underdiagnosed in the general population because owners may not seek help until the behavior is severe.

Clinical characteristics of CD can include a diverse group of behaviors (**Table 1**, next page) and can be classified as locomotor, visual or hallucinatory, oral,

or self-directed. The pathophysiology of canine CD is likely multifactorial, considering the range of clinical presentations. Manifestation of CD may be partly dictated by genetics due to breed predilections (**Table 1**, next page), and CD incidence may be higher in specific pedigrees.^{2,4} Geneticists have identified an allele in Doberman pinschers with flank sucking that occurs more frequently in affected dogs.⁵

Neuroimaging studies of dogs with CD have demonstrated altered function in the subcortical region of the brain, including the cortico-striato-thalamo-cortical pathways implicated in human obsessive-compulsive disorder.⁶ These brain regions are associated with serotonergic and dopaminergic systems; in a study, dogs with CD had lower serotonin-receptor binding as compared with dogs in an unaffected control group.⁶ Dogs with CD treated with serotonergic and dopaminergic

CD = compulsive disorder

drugs (eg, clomipramine, fluoxetine) have shown improved clinical signs,⁷⁻¹³ which supports the role neurotransmitters play in dogs with CD.

Learning can affect development and continuation of CD.¹⁴ Situations that incite anxiety, frustration, and/or conflict may cause engagement in displacement or redirected behavior (**Table 2**), which can reduce anxiety and provide a coping mechanism that may result in recurring and repetitive behavior. Pet owners may also perpetuate the behavior through inadvertent reinforcement.¹⁴ Over time, the behavior may become ingrained and uncoupled from the original trigger.

It is unknown if dogs have recurrent, distressing thoughts (ie, obsessions) that may compel performance of repetitive behavior, so use of the term *obsessive* as it applies to dogs with CD has fallen out of favor. Similarly, use of the term *compulsive* to describe any repetitive behavior is discouraged to avoid unintentionally dissuading investigation of other physical or psychological causes of abnormal repetitive behavior.

History & Clinical Signs

Clinical signs often manifest before a dog is 1 year of age.^{2,4,8} The median age of onset is <1 year for tail chasing and flank sucking^{2,4} and >1 year for

TABLE 1

CHARACTERISTICS OF CANINE COMPULSIVE DISORDER²

Category	Repetitive Behavior	Breed Predilections	Possible Concurrent Physical Examination Findings	Physical Differential Diagnoses*
Locomotor	Circling/spinning Tail chasing Pacing	German shepherd dogs Bull terriers Australian cattle dogs	Muscular, orthopedic, or neurologic repetitive stress injuries Difficulty maintaining weight Self-injury from tail biting	Lumbosacral or other neurologic disease Orthopedic disease Seizures [†]
Visual or hallucinatory	Light or shadow chasing Fly snapping	Cavalier King Charles spaniels Border collies Terriers	Cervical pain secondary to chronic cervical hyperflexion or extension Nasal or nasal planum abrasions Repetitive stress injuries from pouncing	Syringomyelia Ocular disease
Oral	Pica Licking	Possibly large-breed dogs	GI disease Foreign body ingestion Fractured or worn teeth	Polyphagia Iron deficiency GI disease Pruritus and/or allergies
Self-directed or self-injurious	Flank sucking Hind checking Acral lick dermatitis	Doberman pinschers Schnauzers Large-breed dogs	Self-inflicted excoriation or injury Alopecia or pyoderma Repetitive stress injuries from spinal flexion	Flank sucking: neurologic disease, GI disease Hind checking: neurologic disease, uroliths Acral lick dermatitis: previous injury, foreign body, osteoarthritis, dermatologic disease

*Pain and neurologic disorders (eg, seizures) are physical differentials for all repetitive behaviors.

†Seizures have been specifically implicated as a cause of tail chasing in bull terriers.²⁰

acral lick dermatitis.^{2,13} Dogs with CD may not be presented until the dog is older because owners may consider repetitive behavior in young dogs to be normal and not seek treatment until the behavior intensifies.¹

Physical examination and diagnostic testing may reveal abnormalities secondary to chronic CD behavior (**Table 1**). Behavior comorbidities (eg, separation anxiety, aggression, generalized anxiety, attention-seeking disorder) are also common. In a study, 75% of dogs diagnosed with CD had a concurrent behavior disorder diagnosis.⁸

Diagnosis

CD is a diagnosis of exclusion; behavioral diagnoses can only be made after physical causes of repetitive

behavior have been ruled out (**Figure 1**, page 57). **Table 1** includes a brief list of medical differentials for various canine compulsive behaviors.

A thorough behavior history—including, but not limited to, a description or documentation of the behavior (ideally, a video), initiating factors, situations in which the behavior is likely to occur, owner response, and previous treatment attempts and degree of success—should be obtained before a diagnosis is made. Behavior history forms are available (see **Suggested Reading**, page 83) and can be useful for identification of comorbid behavior disorders.

CD = compulsive disorder

Continues ►

TABLE 2

DEFINITIONS & EXAMPLES OF DIFFERENTIAL DIAGNOSES FOR REPETITIVE BEHAVIOR²

Differential Diagnosis	Definition	Example
Displacement behavior	Normal behavior displayed at inappropriate times, or out of context, in response to anxiety-provoking events	Dog with noise aversion that spins during fireworks
Redirected behavior	Behavior incited by one target but directed at another	Pruritic dog that licks inside of an Elizabethan collar when it cannot lick itself
Vacuum activity	Behavior performed in absence of normal stimuli required for that behavior	Border collie that runs laps when not exercised
Stereotypy	Repetitive, unvarying behavior with no apparent goal or function displayed by captive animals lacking appropriate enrichment or outlets	Dog confined to a small kennel without toys or social contact that jumps on the door in an invariant pattern
Audience-responsive behavior	Operant-conditioned behavior performed to solicit interaction with humans and in the presence of a human and has past reinforcement	Light-chasing dog that stops when owner leaves and has historically been offered a toy when it chased lights

Not all repetitive behavior is compulsive; differential diagnoses for repetitive behaviors are listed and defined in **Table 2**, previous page. An audience-responsive component should be considered if there is a history of reinforcement and if the behavior primarily occurs in the presence of humans, stops when the owner walks away, or

stops when the dog receives a reward. Displacement behavior (eg, a dog licking its paw when alone) typically occurs during stressful situations and remains linked to an anxiety-provoking event but can evolve into CD with repetition or additional stress.

After physical and alternative behavior explanations have been excluded, an abnormal repetitive behavior that affects a dog's quality of life may be attributed to CD (**Figure 2**).

Treatment & Management

Treatment of CD can include providing owner education, minimizing repetitive behavior, reinforcing alternative behavior, and/or alleviating patient stress.

Punishment-based training should not be used, as it can increase aggression, the likelihood for injury,¹⁵ and anxiety, which may exacerbate CD behavior.² Pet owners may be less likely to use punishment-based training if educated that CD is associated with anxiety, not dominance behavior or lack of training.

To prevent unintentional reinforcement of CD behavior, pet owners should not provide or remove positive reinforcements (eg, attention, food, toys) when the dog engages in repetitive behavior. Because CD behavior becomes more ingrained the more frequently it is practiced, treatment should focus on behavior prevention. Pet owners can identify situations in which CD behavior is likely to occur to help with avoidance (eg, restricting yard access to prevent the dog from repetitively running laps around the perimeter).

Dogs should be taught an alternative behavior that can be cued and reinforced when the compulsive behavior is likely to occur. Dogs that pace may be encouraged to fetch an object. Dogs that shadow chase may be rewarded for lying down with their chin on the floor. Dogs with pica may be fed exclusively from puzzle toys, which also provide mental enrichment.



▲ **FIGURE 2** A 7-year-old neutered male dachshund with a 6-year history of circling and tail chasing. Although situations that caused the dog excitement (eg, noise, visitors) initiated bouts of circling, he would also circle when alone and in the absence of identifiable triggers (see **Video**). MRI of the brain was unremarkable, but spinal MRI revealed severe right-sided disk herniation from L6 to L7. Clinical signs did not improve following dorsal lumbosacral decompression surgery and treatment with NSAIDs on recovery. A diagnosis of CD with intervertebral disk disease secondary to chronic circling was made. Clomipramine (2 mg/kg q12h) and a behavior modification plan were implemented. Circling decreased in frequency and intensity but occasionally occurred in periods of heightened stress (eg, crying baby).

Pet owners should not interact with their pet in an inconsistent manner (eg, when a dog jumps in greeting and is alternately praised and punished). Inability to predict how a human will respond may cause the dog to feel anxious, confused, and/or frustrated; consistent, predictable interactions can help alleviate stress. A cue–response–reinforcement pattern in which a cue (eg, sit command) is given, the dog responds (eg, dog sits), and the desired behavior is reinforced (eg, a treat is given) is recommended. The consequence of undesirable behavior should be withdrawal of attention (eg, owner walks away when the dog jumps up).

Environment modification and/or physical restraint may be necessary to prevent engagement in CD behavior. Opaque privacy film on reflective surfaces can reduce light chasing. Dogs that pace in the yard can eliminate while on a leash. Barriers (eg, baby gates, pens, crates, tethers) can prevent access to trigger environments and restrict movement, which can minimize repetitive locomotor behavior. Dogs with self-injurious behavior may require basket muzzles, bandages, or Elizabethan collars, although the CD behavior may recur once these are removed.²

Because CD is associated with anxiety, psychopharmaceuticals that affect serotonin can reduce the frequency and intensity of CD behavior. Clomipramine (1-2 mg/kg PO q12h), a primarily serotonergic tricyclic antidepressant, has been the drug of choice to treat CD and has shown efficacy in the treatment of tail chasing in terriers and other repetitive behaviors.⁸⁻¹¹ Fluoxetine (1-2 mg/kg PO q24h), a selective serotonin reuptake inhibitor, has been shown to be as effective as clomipramine in the treatment of tail chasing in dogs¹¹ and more effective than placebo in the treatment of acral lick dermatitis.¹³ In a placebo-controlled clinical trial, owners of dogs given fluoxetine were significantly more likely to report a reduction in the perceived severity (ie, absent, mild, moderate, severe, very severe) of their dog's CD behavior than owners of dogs given placebo; however, a significant difference in frequency and duration of CD behavior

between fluoxetine- and placebo-treated groups was not found.¹² Doses of clomipramine and fluoxetine used to treat CD varied between studies.⁹⁻¹³ One study reported that, although not definitively determined in dogs, clomipramine at 3 mg/kg PO q12h significantly reduced the severity of CD behavior.¹⁰ In another study, clomipramine was increased above the initial starting dose (1-2 mg/kg PO q12h) in 3 of 18 dogs to reduce tail chasing.⁹ In humans, treatment of obsessive-compulsive disorder typically requires higher doses of pharmaceutical agents as compared with other anxiety disorders.¹⁶

There are no FDA-approved medications for CD treatment in dogs. Because medications to treat CD behavior are extra-label, informed owner consent should be obtained, particularly because higher doses may be necessary in some patients and there may be a higher risk for adverse effects. Caution should be taken in dogs with cardiovascular disease. In humans, tricyclic antidepressants (eg, clomipramine) are associated with adverse cardiovascular effects (eg, arrhythmias) and prolongation of the QT interval on ECG.¹⁷ In a study of dogs, serum clomipramine concentration was positively correlated with an increase in P-wave duration but was not significantly correlated with QT

VIDEO

Scan the QR code to watch a video of a dachshund exhibiting tail chasing.



Using QR codes from your mobile device is easy and quick!

Simply focus your phone's camera on the QR code as if taking a picture (but don't click!). A notification banner will pop up at the top of your screen; tap the banner to view the linked content.

CD = compulsive disorder

interval.¹⁸ However, in a drug safety study, bradycardia and arrhythmias were observed in some dogs that received ≤ 20 mg/kg/day for 6 months.¹⁹

Prognosis

Prognosis for CD is guarded to fair, and owner expectations should be managed. Reduction of the severity and frequency of CD behavior is a realistic treatment goal, as it is unlikely treatment will stop repetitive behavior completely. Treatment should focus on improving quality of life (eg, limiting self-injury, allowing opportunities for enjoyable activities, distracting from repetitive behavior).

Clinical Follow-Up & Monitoring

Frequent communication between the clinician and pet owner is essential for monitoring the patient's response to treatment and providing adjustments as needed. Situations that increase stress (eg, moving, new pet or household member) may trigger a relapse in CD behavior; owners should be encouraged to contact the clinician if necessary. Preemptive intervention before CD behavior affects the dog's or pet owner's quality of life typically provides the highest likelihood for success for CD treatment in dogs. ■■■

CD = compulsive disorder

References

- Hewson CJ, Luescher UA, Ball RO. The use of chance-corrected agreement to diagnose canine compulsive disorder: an approach to behavioral diagnosis in the absence of a 'gold standard.' *Can J Vet Res.* 1999;63(3):201-206.
- Tynes VV, Sinn L. Abnormal repetitive behaviors in dogs and cats: a guide for practitioners. *Vet Clin North Am Small Anim Pract.* 2014; 44(3):543-564.
- Denenberg S, Landsberg GM, Horwitz D. A comparison of cases referred to behaviorists in three different countries. In: Mills DS, Levine E, Landsberg, et al, eds. *Current Issues and Research in Veterinary Behavioral Medicine: Papers Presented at the 5th International Veterinary Behavior Meeting.* West Lafayette, IN: Purdue University Press; 2005:56-62.

Continues on page 83 ►

Semintra® (telmisartan oral solution) 10 mg/mL

For oral use in cats only

Angiotensin II Receptor Blocker

Brief Summary: Before using SEMINTRA, please consult the product insert, a summary of which follows:

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description: SEMINTRA (telmisartan oral solution) is a clear, colorless to yellowish viscous solution containing 10 mg/mL telmisartan.

Indication and Usage: SEMINTRA is indicated for the control of systemic hypertension in cats. The initial dose of SEMINTRA is 1.5 mg/kg (0.68 mg/lb) orally twice daily for 14 days, followed by 2 mg/kg (0.91 mg/lb) orally once daily. The dose may be reduced by 0.5 mg/kg (0.23 mg/lb) increments to a minimum of 0.5 mg/kg (0.23 mg/lb) orally once daily to manage SEMINTRA-induced hypotension. SEMINTRA can be administered directly into the mouth, or next to or on top of a small amount of food. Do not mix into food. SEMINTRA should be administered using the dosing syringe provided in the package. The dosing syringe fits onto the bottle and has 0.1 mL incremental marks. The dose should be rounded to the nearest 0.1 mL. After administration close the bottle tightly with the cap. Rinse the dosing syringe with water and let air dry. If the cat vomits within 30 minutes of dosing, the cat may be re-dosed.

Information for Cat Owners: Adverse reactions can occur with use of SEMINTRA. The most common adverse reactions reported during the field studies included vomiting, diarrhea, lethargy, weight loss, anemia, and dehydration.

Contraindications: Do not use in cats with a hypersensitivity to telmisartan.

Human Warnings: Not for human use. Keep out of reach of children.

SEMINTRA is an angiotensin II antagonist/angiotensin receptor blocker (ARB). Pregnant women should avoid contact with SEMINTRA because substances that act on the renin-angiotensin-aldosterone system (RAAS) such as angiotensin receptor blockers (ARBs) can cause fetal and neonatal morbidity and death during pregnancy in humans.

Precautions: SEMINTRA can cause mild anemia or non-regenerative anemia. Cats should be monitored for anemia when initiating treatment with SEMINTRA.

SEMINTRA may cause inappetence and weight loss in some cats. Cats should be monitored for weight loss when initiating treatment with SEMINTRA. Use with caution in cats with a history of vomiting, inappetence, or weight loss.

SEMINTRA has not been evaluated in cats with systolic blood pressure >200 mmHg.

The safe use of SEMINTRA in cats with hepatic disease has not been evaluated. SEMINTRA is metabolized by the liver.

The safe use of SEMINTRA has not been evaluated in cats less than 9 months of age, or in cats that are pregnant, lactating, or intended for breeding. **See Human Warnings.**

The safe use with other anti-hypertensive medications has not been evaluated.

Adverse Reactions: The safety of SEMINTRA was evaluated in a 28-day field study in 192 cats. Adverse reactions that occurred include vomiting 46 (24.0%), diarrhea 18 (9.4%), lethargy 13 (6.8%), weight loss 13 (6.8%), decreased appetite/inappetence 13 (6.8%), non-regenerative anemia 11 (5.7%), dehydration 10 (5.2%), retinal lesions (target organ damage) 4 (2.1%).

The long-term safety of SEMINTRA was evaluated in an open-label, 5-month field effectiveness and safety study in 107 cats that received at least one dose of SEMINTRA. Adverse reactions that occurred in this study are weight loss 37 (34.6%), vomiting 32 (29.9%), dehydration 18 (16.8%), non-regenerative anemia 17 (15.8%), anorexia 14 (13.1%), diarrhea 12 (11.2%), lethargy 12 (11.2%), decreased appetite/inappetence 11 (10.3%), heart murmur 10 (9.3%), death, euthanasia, found dead 9 (8.4%), cough 8 (7.5%), and retinal lesions (target organ damage) 6 (5.6%).

Nine cats died or were euthanized during the study. Three cats had progressive chronic kidney disease that may have been affected by telmisartan treatment, concurrent disease, or inadequate control of hypertension. The other six cats died of causes unrelated to treatment (e.g. neoplasia).

To report suspected adverse drug events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer Ingelheim Vetmedica, Inc. at 1-866-638-2226. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

Effectiveness: Effectiveness was demonstrated in a 28-day multi-center, controlled, randomized and masked field study in client-owned cats with hypertension, and in an open-label 5-month field study.

28-Day Field Study

In a 28-day study, 288 cats with hypertension (systolic blood pressure [SBP] 160-200 mmHg) were enrolled in the study and randomized to treatment with SEMINTRA (telmisartan oral solution) (n=192) or vehicle control (n=96). The study population included cats with hypertension associated with chronic kidney disease or controlled hyperthyroidism, or idiopathic hypertension. The per protocol population for effectiveness was 141 SEMINTRA treated cats and 79 control cats. SEMINTRA was administered orally at 1.5 mg/kg twice daily for 14 days, then 2 mg/kg once daily until study end; the vehicle control was administered at a mL/kg volume equivalent to SEMINTRA. The two primary variables for effectiveness were comparison of the SEMINTRA and control group mean SBP (mSBP) from baseline to Day 14, and a decrease in mSBP >20 mmHg in the SEMINTRA group from baseline to Day 28. Cats with SBP >180 mmHg at Days 14 or 28 were rescued and removed from the study. There was a statistically significant difference between the mSBP for the SEMINTRA group compared to the control group at Day 14 (p=0.0005). At Day 14 the SEMINTRA group mSBP decreased by 23.2 mmHg, and the control group mSBP decreased by 7.3 mmHg. At Day 28, the SEMINTRA group mSBP decreased 23.9 mmHg compared to baseline.

5-Month Field Study

One hundred-seventy cats from the SEMINTRA group that had successfully completed the 28-day study were enrolled in a 5-month open-label study. At the beginning of the 5-month study most cats were administered SEMINTRA at 2 mg/kg once daily. Cats that experienced hypotension (defined as SBP <120 mmHg) at 2 mg/kg once daily could have the SEMINTRA dose reduced to 1 mg/kg once daily. Cats that experienced hypotension at 1 mg/kg once daily could have the SEMINTRA dose reduced again to 0.5 mg/kg once daily. Cats were evaluated for SBP, target organ damage (TOD; primarily assessed by retinal photographs), clinical pathology and adverse reactions. SBP was measured on Days 28, 56, 98, 140 and 182 and retinal photographs and clinical pathology were collected on Days 28, 98 and 182. Seventy-three (68.2%) cats completed the study (Day 182), 8 cats were removed for hypertension (SBP >180 mmHg), 2 cats were removed for hypotension, 10 cats were removed by the owner or for owner non-compliance, 8 cats were removed for new or worsening TOD, and 6 cats were removed for adverse reactions unrelated to TOD. Twenty-six cats had dose reductions to 1 mg/kg once daily to manage hypotension. Of these 26 cats, 10 had an additional dose reduction to 0.5 mg/kg once daily.

NADA 141-501, Approved by FDA

Manufactured for:

Boehringer Ingelheim Vetmedica, Inc.
St. Joseph, MO 64506, U.S.A.

SEMINTRA is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license.

© 2018 Boehringer Ingelheim Vetmedica, Inc. All Rights Reserved.

Reference: Package Insert 449201-00 Revised 03/2018

09/2018

ADVERTISERS INDEX

The *Clinician's Brief* Advertisers Index is provided as a service to our readers. The publisher does not assume responsibility for any errors or omissions.

- Advantage Multi for Cats** | LayersofMulti.com | pages 51, 50 | Bayer Animal Health
- Apoquel** | apoquel.com | pages 25, 24 | Zoetis
- Clinical Report: The Elusive Feline Heartworm Diagnosis** | LayersofMulti.com | pages 52-53 | Bayer Animal Health
- Clinician's Brief Career Center** | cliniciansbrief.com/career-center | page 79 | *Clinician's Brief*
- Clinician's Forum: Understanding Apoquel & Dispelling the Myths** | apoquel.com | outsert | Zoetis
- CR7 VET Dental X-Ray** | im3vet.com | inside back cover | iM3
- Credelio** | credelio.com | cover insert | Elanco
- Doxidyl** | doxidl.com | pages 8, 10 | Ceva Animal Health
- Duramune Lyme** | elanco.com | page 71 | Elanco
- Entyce** | entyce.aratana.com | pages 37, 36 | Aratana Therapeutics
- Galliprant** | canineOASTories.com | pages 32-33 | Elanco
- Glandex** | glandex.com/vets | page 38 | Vetrinque Labs
- HEARTGARD Plus** | heartgard.com | pages 17, 16 | Boehringer Ingelheim
- Hill's to Home** | Vet.HillsToHome.com | inside front cover; page 1 | Hill's Pet Nutrition
- Mason Company Surgery Recovery** | MasonCo.com/surgery | page 43 | Mason Company
- Mirataz** | kindredbio.com/Mirataz | pages 2, 4 | Kindred Bio
- Mobility Solutions** | boehringer-ingelheim.com | pages 45-47 | Boehringer Ingelheim
- New York Vet** | newyork.vetshow.com; vetshow.com | page 56; outsert | CloserStill Vet US
- NexGard Chewables** | NexGardClinic.com | back cover; page 82 | Boehringer Ingelheim
- Nocita** | nocita.aratana.com | pages 65, 64 | Aratana Therapeutics
- Nutrition Exchange** | PurinaVeterinaryDiets.com | insert | Nestlé Purina Company
- OraVet** | oravet.com | page 31 | Boehringer Ingelheim
- Preputial Plasty for Feline Phimosis Utilizing CO₂ Laser** | aesculight.com/video | pages 80-81 | LightScalpel
- Pro Plan Vet Direct** | ProPlanVetDirect.com | page 48 | Nestlé Purina Company
- Profender** | BayerDVM.com | pages 6, 5 | Bayer Animal Health
- PureVax** | PetVaccinesClinic.com | page 34 | Boehringer Ingelheim
- Rescue Disinfectants** | rescuedisinfectants.com | page 26 | Virox Animal Health
- Royal Canin Urinary Health** | royalcanin.com | page 12 | Royal Canin
- Semintra** | semintra.com | pages 63, 62 | Boehringer Ingelheim
- Stokes Pharmacy** | stokes503B.com | page 55 | Stokes Pharmacy
- Vetoryl Capsules** | dechra-us.com | pages 41, 40 | Dechra
- WVC 92nd Annual Conference** | wvc.org/conference | page 72 | Western Veterinary Conference
- Photo Credits**
© Shutterstock.com pages 14, 19, 35

CONSULT THE EXPERT ▶ CONTINUED FROM PAGE 62

References

- Escriviou C, Renier S, Tiira K, et al. Phenotypic and genetic characterization of "spinning" or "tail-chasing" in bull terriers. *J Vet Behav.* 2012;7(6):e4-e5.
- Dodman NH, Karlsson EK, Moon-Fanelli A, et al. A canine chromosome 7 locus confers compulsive disorder susceptibility. *Mol Psychiatry.* 2010;15(1):8-10.
- Stein DJ. Obsessive-compulsive disorder. *Lancet.* 2002;360(9330):397-405.
- Vermeire S, Audenaert K, Dobbelaire A, Vandermeulen E, Waelbers T, Peremans K. A Cavalier King Charles dog with shadow chasing: clinical recovery and normalization of the dopamine transporter binding after clomipramine treatment. *J Vet Behav.* 2010;5(6):345-349.
- Overall KL, Dunham AE. Clinical features and outcome in dogs and cats with obsessive-compulsive disorder: 126 cases (1989-2000). *J Am Vet Med Assoc.* 2002;221(10):1445-1452.
- Moon-Fanelli AA, Dodman NH. Description and development of compulsive tail chasing in terriers and response to clomipramine treatment. *J Am Vet Med Assoc.* 1998;212(8):1252-1257.
- Hewson CJ, Luescher UA, Parent JM, Conlon PD, Ball RO. Efficacy of clomipramine in the treatment of canine compulsive disorder. *J Am Vet Med Assoc.* 1998;213(12):1760-1766.
- Yalcin E. Comparison of clomipramine and fluoxetine treatment of dogs with tail chasing. *Tierarztl Prax Ausg K Kleintiere Heimtiere.* 2010;38(5):295-299.
- Irimajiri M, Luescher AU, Douglass G, Robertson-Plouch C, Zimmermann A, Hozak R. Randomized, controlled clinical trial of the efficacy of fluoxetine for treatment of compulsive disorders in dogs. *J Am Vet Med Assoc.* 2009;235(6):705-709.
- Wynchank D, Berk M. Fluoxetine treatment of acral lick dermatitis in dogs: a placebo-controlled randomized double blind trial. *Depress Anxiety.* 1998;8(1):21-23.
- Hall NJ, Protopopova A, Wynne CDL. The role of environmental and owner-provided consequences in canine stereotypy and compulsive behavior. *J Vet Behav.* 2015;10(1):24-35.
- Herron ME, Shofer FS, Reiser IR. Survey of the use and outcome of confrontational and non-confrontational training methods in client-owned dogs showing undesired behaviors. *Appl Anim Behav Sci.* 2009;117(1-2):47-54.
- Sadock BJ, Sadock VA. Obsessive-compulsive disorder. In: Sadock BJ, Sadock VA. *Synopsis of Psychiatry.* 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:604-612.
- Stahl SM. Clomipramine. In: Stahl SM. *Essential Psychopharmacology: The Prescriber's Guide.* 3rd ed. Cambridge, UK: Cambridge University Press; 2009:89-95.
- Reich MR, Ohad DG, Overall KL, Dunham AE. Electrocardiographic assessment of anti-anxiety medication in dogs and correlation with serum drug concentration. *J Am Vet Med Assoc.* 2000;216(10):1571-1575.
- Clomicalm [package insert]. Greenfield, IN: Elanco; 2008.
- Dodman NH, Knowles KE, Shuster L, Moon-Fanelli AA, Tidwell AS, Keen CL. Behavioral changes associated with suspected complex partial seizures in bull terriers. *J Am Vet Med Assoc.* 1996;208(5):688-691.

Suggested Reading

- Bain M, Reich M. Tail chasing, leg licking-can't you stop? Compulsive behaviors. In: Horwitz DF, Ciribassi J, Dale S, eds. *Decoding Your Dog.* New York, NY: Houghton Mifflin Harcourt; 2014:281-295.
- Sinn L. The behavioral assessment. *Veterinary Team Brief.* 2018;6(5). <https://www.cliniciansbrief.com/article/behavioral-assessment>. Accessed May 5, 2019.
- Tynes VV, Sinn L. Abnormal repetitive behaviors in dogs and cats: a guide for practitioners. *Vet Clin North Am Small Animal Pract.* 2014;44(3):543-564.